Key result
Intravenous nitroglycerin increases coronary artery stenosis diameter by ~15% compared to placebo.
Why the study?
The role of low dose intravenous nitroglycerin in dilating coronary stenoses and its relation to antianginal effects was investigated.
Does 0.025 mg intravenous nitroglycerin dilate coronary stenoses in patients with coronary heart disease?
RCT (n=40)
Double-blind
randomized
Does 0.025 mg intravenous nitroglycerin dilate coronary stenoses in patients with coronary heart disease?
p-value: p=<0.01
Low-dose intravenous nitroglycerin significantly dilates coronary stenoses without causing strong hemodynamic effects, suggesting this mechanism plays an important role in its antianginal action.
Low-dose IV nitroglycerin dilates stenoses without hemodynamic effects; confirms stenosis dilation as a key antianginal mechanism in CAD.
In a randomized double-blind study, 40 patients with coronary heart disease received either 0.025 mg nitroglycerin or placebo intravenously. Before and 2-3 min after injection, the aortic and left ventricular pressures were recorded and coronary angiography was performed. Mean heart rate, systolic and diastolic aortic pressure, left ventricular filling pressure and the pre- and poststenotic coronary artery diameters, as well as the diameters of representative distal coronary artery segments showed no significant changes. Coronary artery stenosis diameters remained unchanged after placebo (1.01 +/- 0.5 to 1.13 +/- 0.49 mm; n.s.) but increased significantly after nitroglycerin from 1.15 +/- 0.68 to 1.32 +/- 0.73 mm (P less than 0.01). Since it has been demonstrated, on the other hand, that the same dose of nitroglycerin reveals antianginal activity, it can be hypothesized from these results that dilatation of coronary stenoses plays an important role in the antianginal action of nitroglycerin. Strong haemodynamic effects do not appear to be a prerequisite of the beneficial effects of nitroglycerin.
No takes yet. Share an insight, caveat, or question.
Sievert et al. (1989) conducted an RCT in coronary heart disease (n=40). nitroglycerin vs. placebo was evaluated on Coronary artery stenosis diameters (p=<0.01). Intravenous nitroglycerin (0.025 mg) significantly increased coronary artery stenosis diameters from 1.15 mm to 1.32 mm (P<0.01), whereas placebo showed no significant change.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: